医学
围手术期
外科
麻醉
脊柱侧凸
输血
体质指数
置信区间
抗纤维溶解
血容量
前瞻性队列研究
氨甲环酸
内科学
失血
作者
Pierre Pardessus,Maud Loiselle,V. Silins,Anne‐Laure Hörlin,Kelly Brouns,Lucile Marsac,Charlotte Fait,Brice Ilharreborde,Florence Julien‐Marsollier,Souhayl Dahmani
摘要
Abstract Introduction Bleeding and transfusion remain important concerns during surgical correction of scoliosis even when multiple conservative strategies, such as preoperative recombinant erythropoietin and/or antifibrinolytic agents, are used. The current work aimed to determine the impact of other potential risk factors, especially the volume of intraoperative fluid intake, on the perioperative risk of allogenic transfusion during surgical correction of adolescent idiopathic scoliosis. Methods This prospective study included all cases of adolescent idiopathic scoliosis operated in a single center during 2 years (2018–2020). Predictors analyzed were as follows: body mass index, preoperative hemoglobin concentration, thoracoplasty, preoperative halo‐gravity, volume of intraoperative crystalloid administration, use of esophageal Doppler (for goal‐directed fluid therapy), and duration of surgery. Statistical analyses were performed using a multivariable logistic regression model. Results Two hundred patients were included in the analysis. Multivariable analysis found: an increased volume of intraoperative crystalloid administration as a significant predictor of allogenic blood transfusion. Receiving operator characteristics analysis found the model exhibiting an area under the curve of 0.85 (95% confidence interval: 0.75–0.95). Optimizing stroke volume using esophageal Doppler was associated with a decrease in intraoperative crystalloid intake. Conclusion These results indicate a statistical association between the increase in crystalloid intake and the risk of allogenic blood transfusion during surgical correction of adolescent idiopathic scoliosis. Controlled studies are needed to address the causative relation between intraoperative fluid intake and the risk of allogenic transfusion.
科研通智能强力驱动
Strongly Powered by AbleSci AI